An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.
The OOBRAF OOgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The OOBRAF OOV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. OOFurthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, OO54% Erdheim-Chester disease, 38% of Langerhans cell histocytoses OOand 60% of pleomorphic xanthoastrocytomas. OO
200ug/ml of Ab purified from rabbit anti-serum by Protein A. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.
Antibody Type:
Monoclonal Antibody
Application Notes:
ELISA (For Coating, order Ab without BSA),Optimal dilution for a specific application should be determined.
SDS-PAGE Analysis of Purified BRAF Mouse Monoclonal Antibody (V600E/1322). Confirmation of Purity and Integrity of Antibody.
* VAT and and shipping costs not included. Errors and price changes excepted
